全球首款个体化mRNA肿瘤疫苗今年8月份试验成功后,正在重新点燃该赛道热度。 “2022年、2023年后,生物医药行业进入资本寒冬,mRNA赛道更是遇冷。新冠mRNA疫苗大获成功之后,市场一直质疑mRNA技术能否拓展到治疗领域。此前和投资人交流时,大家普遍认为mRNA治疗赛道不确定性很高。”近日,在2026(第三届)BIOCHINA华南生物产业大会上,惠正奇董事长兼CEO回爱民说,莫德纳的...
Source Link全球首款个体化mRNA肿瘤疫苗今年8月份试验成功后,正在重新点燃该赛道热度。 “2022年、2023年后,生物医药行业进入资本寒冬,mRNA赛道更是遇冷。新冠mRNA疫苗大获成功之后,市场一直质疑mRNA技术能否拓展到治疗领域。此前和投资人交流时,大家普遍认为mRNA治疗赛道不确定性很高。”近日,在2026(第三届)BIOCHINA华南生物产业大会上,惠正奇董事长兼CEO回爱民说,莫德纳的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.